On track for first autoimmune drug approval, Bing Yao steers AstraZeneca spinoff to $150M IPO
Just days after Viela Bio secured its first PDUFA date for its lead autoimmune drug, the AstraZeneca spinoff is confidently gunning for a $150 million IPO.
The biotech is dedicating most of the proceeds to three assets — out of six it got from a cleanup at MedImmune before the biologics unit got restructured altogether. Chief among them would be inebilizumab, the anti-CD19 drug that’s being ushered through the BLA approval process for neuromyelitis optica spectrum disorder, prepped for commercialization and explored in additional indications. Then there’s also the CD40L-targeting VIB4920, for which Phase II studies are planned for later this year; and the Phase Ib antibody VIB7734, which inhibits ILT7.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
